ISSN: 2278-0238

Revue internationale de recherche et développement en pharmacie et sciences de la vie

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

CYTOTOXIC SYMMETRICAL THIAZOLEDISELENIDES WITH INCREASED SELECTIVITY AGAINST MCF-7 BREAST CANCER CELLS

Saad Shaaban, Hatem E. Gaffer, Mohannad Alshahd, and Saad S. Elmorsy

A novel series of symmetrical thiazolediselenides were synthesized in good to moderate yields and there in vitro cytotoxic activity was evaluated against
breast adenocarcinom (MCF-7) and compared with their cytotoxicity in normal fibroblast cells (WI-38) employing standard MTT assay. Additionally, there in vitro
antimicrobial activities were also evaluated against gram-negative (Escherichia coli), gram-positive (Staphylococcus aureus) bacteria and a pathogenic yeast
(Candida albicans). A significant difference in toxicity zones between breast solid tumor cells and normal WI-38 cells was observed indicating that it is not general
selenium toxicity. Within this context, compounds 4b, 5, 7, 18 and 23 exhibited therapeutic indices (TI) up to eleven fold and in most cases were higher than TI of 5-
fu suggesting their effectiveness as anti-cancer agents. On the other hand, compounds 4a, 5, 7, 18 and 22 exhibited good antibacterial activity against E. coli and
S. aureus bacteria compared to the known drug, ampicillin. Moreover, compounds 4a, 7, 11, 13, 19, 22 and 23 exhibited good antifungal activity against C.
albicans compared to colitrimazole. These initial promising results point to a reasonable activity of some of these compounds, which needs to be further investigated
by using a considerably wider arsenal of human cancer and normal cells as well as humanopathogenic bacteria and fungi.